IM8 hit $100 million in eleven months without a single retail door. That was not an accident.

IM8 Health is a longevity-focused supplement brand co-founded by CEO Danny Yeung, backed by the diagnostics company Prenetics, and David Beckham, who joined at the co-founder level rather than as a paid spokesperson. Yeung has described lengthy conversations with Beckham before the brand launched, with Beckham insisting the product had to be evidence-based and had to genuinely taste good, positioning it as an alternative to the pill-heavy supplement routines he had grown tired of.

IM8 launched in December 2024 and is reported to have reached $100 million in annual recurring revenue within eleven months, entirely through a subscription-only direct-to-consumer model. There is no retail footprint driving that number. For a category where shelf presence is usually treated as the proof a brand has arrived, that is worth sitting with.

Why "no retail yet" can be the correct answer, not the missing piece

A subscription-only model captures nearly all of the customer relationship and the margin. Every layer this site has covered elsewhere, retailer margin, distributor cut, broker commission, trade spend, simply does not exist yet for IM8. That is not a brand behind on distribution. It is a brand keeping 100% of a very large number for as long as the DTC channel keeps growing on its own.

Retail becomes the right move for a brand like this when direct-to-consumer growth starts to plateau, when a specific retailer relationship offers real strategic value beyond revenue, or when a competitor’s shelf presence starts eating into consideration before the DTC funnel ever gets a chance to work. None of those conditions were true for IM8 in its first year, so retail was correctly not on the table.

Retail is a tool for solving a specific problem, discovery, trust, or a plateauing growth curve. A brand that does not have that problem yet is not behind by staying out of it.

What an evidence-based positioning bought the brand

Beckham’s reported insistence on an evidence-based, single-scoop alternative to a pile of separate pill bottles is a positioning decision that travels well in a subscription model specifically, because the entire pitch is built around a daily habit replacing several other daily habits. That is a much harder story to tell in a five-second shelf glance than it is in a video or a product page with room to explain the mechanism. The DTC-only choice and the positioning reinforce each other.

The signal to watch for, if you are building the same way

If your product needs a page of explanation to land, staying DTC-first while that curve is still climbing is not a delay tactic. It is the same decision IM8 made, correctly, for the same reason. The moment to revisit it is when growth flattens, when a specific retail relationship offers something DTC cannot, or when a competitor starts winning the physical shelf you have been ignoring. Watch for those signals rather than assuming retail is simply the next stage everyone eventually reaches.